Speaker Profile

Ph.D., Global ahead of AI Solutions , Novartis Oncology

Biography
Dr. Yurt is the Head of Global AI Solutions for Novartis Oncology . As a business strategist and data science expert, she led several teams in the areas of data science , business analysis, information management and market research within Novartis and other small biotechs.Dr Yurt is a board member of Pharmaceutical Management Science Association since 2013 where she works on bringing new business analysts and data scientists with industry experts.She is also the President of the board for Peace Islands Institute where she partners with interfaith organizations to improve local peace within the NJ community. Dr. Yurt has Ph.D in economics. She studied the effects of social ability on life time earnings at University of Arizona and tought several courses in this subject. Dr.Yurt received several scholarships including George W. Coleman Scholarship at University of Arizona and National Academy of Sciences and Technology of Turkey (TUBITAK) Fellowship award.


 Session Abstract – PMWC 2023 Silicon Valley

Track 2 - January 26 9.00 A.M.-4.30 P.M.


Track Chair: - Courtney McFall, UCSF
- Ben Rubin, UCSF

Patient-centric data – Real-World Evidence (RWE) and Real-World Data (RWD) - is becoming instrumental in the drug development process and for health care decisions in general. This data is not only informative for the process from discovery to new indications, clinical trial design, and drug development, it also can be of value to monitor post-marketing drug safety and for decision support in clinical practice. As the data becomes a decision driver, science companies and medical organizations are increasingly focused on leveraging RWD and RWE to not only better understand the patient populations using their drugs and the respective outcomes, but also to accelerate clinical decision support. This session will focus on the various aspects of integrating RWE and RWD to support drug development and clinical decision support.

Sessions:

  • Clinical Studies Using RWD (PANEL)
    Chair:
    - Liora Schultz, Stanford
    - Sanket Dhurva, UCSF
    - Eze Abosi, Optum Life Sciences
    - Motiur Rahman, FDA
    - Aaron Kamauu, Navidence
  • Beyond the EHR: Acquisition of RWD Types to Enable Precision Medicine (PANEL)
    Chair: Riley Bove, UCSF
    - Anna Berry, Sypase
    - Ashley Brenton, Optum
    - Vasu Chandrasekaran, Ontada
  • Data Linkage, Harmonization, and Quality (PANEL)
    Chair: Vivek Rudrapatna, UCSF
    - Rohit Vashisht, UCSF
    - Adam Asare, QLHC
    - Dan Riskin, Verantos
    - Wanmei Ou, Ontada
    - Mindy DeRouen, UCSF
    - Saurabh Gombar, Atropos Health
  • Using RWE to Uncover and Address Health Disparities (PANEL)
    Chair: Chris Boone, AbbVie
    - Robert Hiatt, UCSF
    - Abasi Ene-Obong, 54gene
    - Nuray Yurt, Novartis Oncology
    - Alice Popejoy, UC Davis Health
    - Vic Spain, Genentech
  • FDA RWD/RWE Draft and Final Guidances
    - Motiur Rahman, FDA
  • From Real-World Data to Regulatory-Grade Real-World Evidence
    Chair: Sheila Walcoff, Goldbug Strategies
  • Session TBA
    Chair: Speaker TBA, Ample